Hennessy Advisors Inc. Acquires 63,013 Shares of Pfizer Inc. $PFE

Key Points

• Hennessy Advisors increased its Pfizer stake by 27% in the second quarter, acquiring 63,013 additional shares and bringing its holdings to 296,113 shares valued at approximately $7.13 million. Institutional investors collectively own 68.36% of Pfizer.
• Analyst sentiment remains cautious, with a consensus “Hold” rating and an average price target of $28.28. Pfizer shares recently traded at $26.77, within a 52-week range of $23.58 to $28.75.
• Pfizer exceeded quarterly expectations, reporting $0.77 in EPS and $15.03 billion in revenue, while revenue grew 2.6% year over year. The company also announced a quarterly dividend of $0.43 per share, representing a 6.4% annualized yield.

Hennessy Advisors Inc. grew its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 27.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 296,113 shares of the biopharmaceutical company's stock after acquiring an additional 63,013 shares during the period. Hennessy Advisors Inc.'s holdings in Pfizer were worth $7,130,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in PFE. Evolution Wealth Management Inc. boosted its stake in Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 566 shares during the period. Godfrey Financial Associates Inc. purchased a new position in shares of Pfizer in the fourth quarter worth $26,000. Keb Asset Management LLC purchased a new position in shares of Pfizer in the second quarter worth $26,000. HFM Investment Advisors LLC boosted its position in shares of Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 427 shares during the last quarter. Finally, Global Trust Asset Management LLC grew its stake in Pfizer by 126.7% during the first quarter. Global Trust Asset Management LLC now owns 1,163 shares of the biopharmaceutical company's stock valued at $33,000 after acquiring an additional 650 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Bank of America reduced their price target on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a report on Friday, July 10th. Royal Bank Of Canada raised shares of Pfizer from an "underperform" rating to a "sector perform" rating and set a $25.00 price objective for the company in a report on Tuesday, June 9th. Weiss Ratings restated a "hold (c)" rating on shares of Pfizer in a research report on Monday, August 3rd. JPMorgan Chase & Co. reduced their target price on Pfizer from $30.00 to $28.00 and set a "neutral" rating on the stock in a report on Wednesday, July 8th. Finally, Guggenheim decreased their target price on Pfizer from $35.00 to $31.00 and set a "buy" rating on the stock in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $28.28.

Pfizer Trading Down 0.1%

PFE stock opened at $26.77 on Friday. The firm has a fifty day moving average price of $25.12 and a 200 day moving average price of $26.20. Pfizer Inc. has a fifty-two week low of $23.58 and a fifty-two week high of $28.75. The firm has a market cap of $152.60 billion, a PE ratio of 35.23 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. During the same quarter in the prior year, the firm earned $0.78 earnings per share. Pfizer's revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 6.4%. The ex-dividend date is Friday, July 24th. Pfizer's dividend payout ratio is currently 226.32%.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CEO Albert Bourla purchased approximately $1 million of Pfizer stock—about 38,000 shares—in his first open-market purchase of the company’s shares. The transaction may reassure investors that management views the current valuation as attractive. Pfizer CEO Buys $1 Million of Company Stock
• Positive Sentiment: The European Medicines Agency validated Pfizer and Valneva’s application for their six-valent Lyme disease vaccine candidate, PF-07307405, beginning the formal review process. The filing is supported by Phase 3 results showing more than 70% efficacy and no significant safety concerns. Validation is an important regulatory milestone, although it does not represent approval. Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
• Positive Sentiment: An updated Korean real-world study of Paxlovid highlighted continued potential value for high-risk COVID-19 patients, supporting Pfizer’s effort to maintain demand for its antiviral as COVID-related revenue normalizes. Pfizer’s Korean Paxlovid Study Signals Ongoing Value in High-Risk COVID Market
• Neutral Sentiment: Erste Group Bank raised its fiscal 2026 EPS forecast, adding modest analyst support. Pfizer’s broader investment case also continues to rely on its non-COVID portfolio, including positive Phase 3 LITFULO data and recently acquired products.
• Negative Sentiment: Investors remain focused on Pfizer’s post-COVID revenue declines, recent intangible-asset impairments, and the discontinuation of its BEQVEZ hemophilia gene therapy, which underscore execution and pipeline risks. Gene Therapy Remains Top-of-Mind in Hemophilia

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source